These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The treatment of severe forms of myasthenia gravis. Iani C; Caramia M; Morosetti M; Loberti M; Palmieri MG; Meloni C; Gallucci MT; Casciani CU; Bernardi G Funct Neurol; 1998; 13(3):231-7. PubMed ID: 9800150 [TBL] [Abstract][Full Text] [Related]
27. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis. Cosi V; Lombardi M; Erbetta A; Piccolo G Acta Neurol (Napoli); 1993 Apr; 15(2):123-31. PubMed ID: 8328322 [TBL] [Abstract][Full Text] [Related]
28. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. Valsakumar AK; Valappil UC; Jorapur V; Garg N; Nityanand S; Sinha N J Rheumatol; 2003 Aug; 30(8):1793-8. PubMed ID: 12913937 [TBL] [Abstract][Full Text] [Related]
30. Beneficial effect of tacrolimus on myasthenia gravis with thymoma. Mitsui T; Kunishige M; Ichimiya M; Shichijo K; Endo I; Matsumoto T Neurologist; 2007 Mar; 13(2):83-6. PubMed ID: 17351528 [TBL] [Abstract][Full Text] [Related]
31. Plasmapheresis in myasthenia gravis. Dau PC Prog Clin Biol Res; 1982; 88():265-85. PubMed ID: 7100216 [TBL] [Abstract][Full Text] [Related]
32. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777 [TBL] [Abstract][Full Text] [Related]
33. [Plasmapheresis in patients with myasthenia gravis]. Konishi T Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364 [TBL] [Abstract][Full Text] [Related]
34. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column]. Yeh JH; Chiu HC J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565 [TBL] [Abstract][Full Text] [Related]
35. Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. Baggi F; Ubiali F; Nava S; Nessi V; Andreetta F; Rigamonti A; Maggi L; Mantegazza R; Antozzi C J Neuroimmunol; 2008 Sep; 201-202():104-10. PubMed ID: 18644634 [TBL] [Abstract][Full Text] [Related]
36. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336 [TBL] [Abstract][Full Text] [Related]
37. Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review. Bennani HN; Lagrange E; Noble J; Malvezzi P; Motte L; Chevallier E; Rostaing L; Jouve T J Clin Apher; 2021 Jun; 36(3):348-363. PubMed ID: 33349954 [TBL] [Abstract][Full Text] [Related]
38. Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine. Mok CC; Ying KY; Mak A; To CH; Szeto ML Rheumatology (Oxford); 2006 Apr; 45(4):425-9. PubMed ID: 16234272 [TBL] [Abstract][Full Text] [Related]
39. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Gajdos P; Chevret S; Clair B; Tranchant C; Chastang C Ann Neurol; 1997 Jun; 41(6):789-96. PubMed ID: 9189040 [TBL] [Abstract][Full Text] [Related]
40. Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy. Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Hardt S; Goeser S; Kaya Z; Katus HA; Dengler TJ J Clin Apher; 2009; 24(4):141-9. PubMed ID: 19591221 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]